Under the terms of the agreement, Champions will use its Tumorgraft platform to test the effectiveness of Teva‘s compound in various cancer indications to assist in further clinical development.
Champions Biotechnology’ technology platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Champions Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor.
Champions Biotechnology said it leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates.
As drugs progress through early stage development, the company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate.
Champions Biotechnology Scientific Operations vice president Elizabeth Bruckheimer said they are very excited to work with Teva on this program.
"The use of our Champions Tumorgraft platform will provide Teva with the data necessary for critical drug development decisions and help focus and accelerate the development program for this compound," Bruckheimer said.